Brepocitinib Beneficial for Moderate-to-Severe Psoriatic Arthritis
Significantly greater ACR20 response rates seen at week 16 for 30 and 60 mg QD versus placebo; response maintained or improved at 52 weeks
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.